Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
196 GBX | -17.65% | -21.60% | -35.74% |
May. 20 | Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study | MT |
May. 20 | Faron Pharma celebrates positive read-out in ongoing MDS trial | AN |
Sales 2024 * | 14.4M 15.61M | Sales 2025 * | 39.09M 42.36M | Capitalization | 201M 218M |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.5M | Net income 2025 * | -4M -4.33M | EV / Sales 2024 * | 16.1 x |
Net Debt 2024 * | 30.6M 33.16M | Net cash position 2025 * | 42.27M 45.8M | EV / Sales 2025 * | 4.07 x |
P/E ratio 2024 * |
-9.12
x | P/E ratio 2025 * |
-18
x | Employees | 34 |
Yield 2024 * |
0.54% | Yield 2025 * |
-
| Free-Float | 60.71% |
Latest transcript on Faron Pharmaceuticals Oy
1 day | -15.18% | ||
1 week | -19.25% | ||
Current month | +39.23% | ||
1 month | +58.34% | ||
3 months | +58.34% | ||
6 months | -23.82% | ||
Current year | -33.81% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 02-12-31 | |
Founder | 46 | 02-12-31 | |
Founder | 70 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 02-12-31 | |
Chairman | 60 | 23-03-23 | |
Founder | 46 | 02-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 196 | -17.65% | 191 671 |
24-05-22 | 238 | 0.00% | 4,846 |
24-05-21 | 238 | -10.19% | 36,719 |
24-05-20 | 265 | +6.00% | 96,746 |
24-05-17 | 250 | 0.00% | 33,416 |
Delayed Quote London S.E., May 23, 2024 at 09:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.81% | 218M | |
+10.29% | 115B | |
+12.28% | 106B | |
-5.84% | 24.69B | |
-1.19% | 21.97B | |
-4.78% | 19.27B | |
-11.50% | 17.56B | |
-39.36% | 17.32B | |
+5.81% | 14.03B | |
+33.13% | 12.13B |
- Stock Market
- Equities
- FARN Stock